Menu
Recruiting NCT07547787

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

— Observational Locally Advanced Unresectable or Metastatic Gastric Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Locally Advanced Unresectable or Metastatic Gastric Cancer. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Overview

This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.

Primary outcome measures

  • Overall Survival (OS) [Time frame: Up to approximately 5 years]

Eligibility criteria

Inclusion criteria

  • Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
  • Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
  • Agree to proceed with the extended follow-up procedures.
  • This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.

Exclusion criteria

  • None

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Peking University Cancer Hospital — Beijing

Identifiers

NCT: NCT07547787 · AK104-EXT-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗